Medicine Overview

Indication

Know Medicine, Follow Guideline

Adult Dose

Clinical InformationAdministration Information
Indication: Photosensitiser in the photodynamic therapy of neovascular age-related macular degeneration
Age: Adult
Dose: Intravenous – 6 mg/m2
Frequency: infusion over 10 minutes, followed by activation using a laser tuned to a wavelength of 689 nm 15 minutes after the start of the infusion
Duration: Repeat every 3 months for recurrent choroidal neovascular leakage
Note: Recommended light dose is 50J/cm2, given over 83 seconds.
Indication: Photosensitiser in the photodynamic therapy of neovascular age-related macular degeneration
Condition: Hepatic impairment: Biliary obstruction; moderate to severe impairment
Dose: Intravenous – 6 mg/m2
Note: Use with caution as no studies done.

Child Dose

Clinical InformationAdministration Information
Age: Child
Dose: No approved pediatric dosage available
Note: Not recommended
Administration
  • Given by IV infusion
  • Eye drops used after infusion
Side Effect

Drug Interaction

Drug NameRisk Factors
Calcium Channel Blockers (Amlodipine, Diltiazem, Verapamil, Nifedipine, Felodipine, Nicardipine, Isradipine), Polymyxin B, Radiation therapy
Increased rate of verteporfin uptake by the vascular endothelium
Photosensitizing Agents (Methoxsalen, Verteporfin)
Increased photosensitivity

Disease Interaction

Disease NameRisk Factors
Porphyria
Risk of acute attacks

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.